HUE033575T2 - Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása - Google Patents

Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása Download PDF

Info

Publication number
HUE033575T2
HUE033575T2 HUE12788871A HUE12788871A HUE033575T2 HU E033575 T2 HUE033575 T2 HU E033575T2 HU E12788871 A HUE12788871 A HU E12788871A HU E12788871 A HUE12788871 A HU E12788871A HU E033575 T2 HUE033575 T2 HU E033575T2
Authority
HU
Hungary
Prior art keywords
group
compound
cancer
formula
methyl
Prior art date
Application number
HUE12788871A
Other languages
English (en)
Inventor
Frank Wu
Aichen Wang
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Publication of HUE033575T2 publication Critical patent/HUE033575T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Description

(12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 239194 <2006 01> C07D 403112 <2006 01) 17.05.2017 Bulletin 2017/20 C07D 471ΙΟ8<200β01> C07D 471Ι10<200β01> A61K 311517<200<S 01> A61K 3115377<200601>
(21) Application number: 12788871.7 Λ61Ρ 35100^1, A61P moo^-OV (22) Date of filing: 28.05.2012 (86) International application number: PCT/CN2012/000737 (87) International publication number: WO 2012/159457 (29.11.2012 Gazette 2012/48)
(54) QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
CHINAZOLINDERIVAT ALS TYROSINKINASEHEMMER, VERFAHREN ZU SEINER HERSTELLUNG UND SEINE ANWENDUNG
DERIVE DE QUINAZOLINE ΕΝ TANT QU’INHIBITEUR DE TYROSINE-KINASE, SON PROCEDE DE PREPARATION ET SON APPLICATION (84) Designated Contracting States: (74) Representative: Croce, Valeria et al AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Jacobacci &amp; Partners S.p.A. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Via Senate, 8 PL PT RO RS SE SI SK SM TR 20121 Milano (IT) (30) Priority: 26.05.2011 CN 201110138115 (56) References cited: E P-A1 - 2 612 860 WO-A1 -2005/107758 (43) Date of publication of application: CN-A- 101 918 390 CN-A-102 382 106 09.04.2014 Bulletin 2014/15 US-A1-2002 082 270 US-A1-2009 306 044 (73) Proprietor: Xuanzhu Pharma Co., Ltd. · HAI-FENG CHEN: "Computational Study of the
Jinan Shandong 250101 (CN) Binding Mode of Epidermal Growth Factor
Receptor Kinase Inhibitors", CHEMICAL
(72) Inventors: BIOLOGY &amp; DRUG DESIGN, BLACKWELL • WU, Frank PUBLISHING TD., OXFORD, GB, vol. 71, no. 5,1
Jinan May 2008 (2008-05-01), pages 434-446,
Shandong 250101 (CN) XP008151012, ISSN: 1747-0277, DOI: • WANG, Aichen 10.1111/J.1747-0285.2008.00656.X [retrieved on
Jinan 2008-03-25]
Shandong 250101 (CN)
Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
Description Technical Field [0001] The present invention belongs to the field of pharmaceutical technology, more specifically relates to a quinazoline derivative as tyrosine kinase inhibitor, a pharmaceutically acceptable salt thereof and a stereoisomer thereof, a preparation method thereof, a pharmaceutical composition containing said derivative and a pharmaceutical formulation containing said derivative, a use of said compound in treating an excessive proliferative disease and a chronic obstructive pulmonary disease, and a use of said compound in the manufacture of a medicamentfortreating an excessive proliferative disease and a chronic obstructive pulmonary disease.
Background Art [0002] The protein tyrosine kinase is an enzyme that catalytically transfers the phosphate group from ATP to the tyrosine residue located at the protein substrate, and has a play in the normal cell growth. Many growth factor receptor proteins operate via the tyrosine kinase, and influence the conduction of signal passage and further regulate the cell growth by this process. However, in some circumstances, these receptors become abnormally due to either the mutation or the overexpression, which cause the uncontrolled cell multipliction, cause the tumor growth, and finally initiate the well-known disease, i.e., cancer. The growth factor receptor protein tyrosine kinase inhibitor, via the inhibition of the above phosphorylation process, may treat cancers and other diseases characterized by the uncontrolled or abnormal cell growth.
[0003] An epidermal growth factor receptor (EGFR) is a multifunction glycoprotein that is widely distributed on the cell membranes of the tissues of the human body, and is an oncogene analog of avian erythroblastic leukemia viral (v-erb-b). Human EGFR/HER1/ErbB-1 and HER2 (human epidermal growth factor receptor-2) /ErbB-2/Teu/p185, HER3/ErbB-3, HER4/ErbB-4 and the like are grouped into the HER/ErbB family, and belong to protein tyrosine kinases (PTKs). It is indicated in the clinical study that EGFR and the like are expressed in the epithelia-derived tumors such as squamous cell carcinoma of head and neck, mammary cancer, rectal cancer, ovarian cancer, prostate carcinoma, non-small cell lung cancer, and the like. Pan-HER tyrosine kinase inhibitor, via the competitive binding the kinase catalytic sites in the intracellular region against ATP, blocks the autophosphorylation of intramolecular tyrosine, blocks the tyrosine kinase activation, inhibits HER family activation, and therefore inhibits cell cycle progression, accelerates cell apoptosis, and exerts the therapeutic action.
[0004] EGFR, after binding the ligand, forms a dimer with a subgroup of HER family, and then combines with ATP to activate the tyrosine kinase activity of the EGFR itself. Therefore, the autophosphorylation occurs in several tyrosine sites of the intracellular kinase region. Pan-HER tyrosine kinase inhibitor, via simultaneity acting on EGFR, and HER2/4, inhibits the activation of HER family, and play a good role in the tumor growth inhibition.
[0005] It is indicated in the study that Pan-HER tyrosine kinase irreversible inhibitor has an inhibition effect on HER2/4, besides it effectively inhibits EGFR. The pharmaceutical drugs of this kind, having an irreversible inhibition to both of HER/ErbB families, not only increase the drug activity, but also reduce the drug resistance, and have a substantial inhibition effect on H1975 cell lines which are resistant to Erlotinib.
[0006] The pharmaceutical drugs that are now commercially available include selective EGFR tyrosine kinase inhibitor Gefitinb (Iressa, ZD1839), Erlotinib (Tarceva, OSI-774) and double EGFR/HER2 inhibitor Lapatinib (Tykerb, GW572016), and their structures are shown below. The above three drugs are all reversible EGF receptor tyrosine phosphorylation kinase inhibitor. It is found in the study that they have good therapeutic response to some tumors initially. However, several months after the treatment, the disease progression appears again and therefore a natural or secondary drug resistance forms.
HfF fX ^«jClp °XqXj
Gefitinb Erlotinib Lapatinib [0007] It is reported in the literature (Bioorganic &amp; Medicinal Chemistry (2008) 16 pages 3482-3488) that the commercially available drugs such as gefitinb and erlotinib have been widely used clinically. The long-term treatment of the late NSCLC (non-small cell lung cancer) may create an acquired drug-resistance, which has a negative effect on the therapeutical effect.
[0008] It is believed that the reversible EFG receptor tyrosine kinase inhibitor competes with ATP for the combination with EFG receptor tyrosine kinase. Due to the relative high concentration of the intracellular ATP (in order of mM), the reversible EGF receptor tyrosine kinase inhibitor, which shows a high acitivity in an in-vitro assay, is difficult to show the effect in the animal pathologic model. The irreversible EGF receptor tyrosine kinase inhibitor does not compete with ATP, and therefore it is expected that the non-reversible EGF receptor tyrosine kinase inhibitor may have a better in-vivo activity.
[0009] W097/38983 discloses irreversible EGF receptor tyrosine kinase inhibitors. For these inhibitors, one Michael receptor is introduced at 6-position of quinazoline, and therefore a Michael addition reaction can be conducted between this receptor and -SH of the cysteine on the pouch wall of the EGF receptor tyrosine kinase activity center (Cys773). Moreover, the activities of these inhibitors and the complexity of the Michael addition reaction between these inhibitors and -SH of the cysteine are in a positive structure-function correlation.
[0010] US20010044435 A1 discloses a quinazoline derivative which has a lactone structure at 6-position of quinazoline. It is believed that it has an inhibition activity for the signal transduction mediated by the tyrosine kinase.
[0011] US20040044014 A1 discloses a quinazoline derivative which has a bridged ring structure at 6-position of quinazoline. It is believed that it has an inhibition activity for the signal transduction mediated by the tyrosine kinase.
[0012] It is reported in the reference (Adv Ther (2011) 28(2) p. 1-8) that PF-299 (Pfizer) and Afatinib (BIBW2992) (Boehringer Ingelheim) are in the clinical stage III, and Neratinib (HKI292) is in the clinical stage II. It is believed that these compounds are inreversible tyrosine kinase inhibitor, and can solve the EGFR resistance.
[0013] It is reported in the references (Cancer Res (2007); 67: (24) p. 11924-11932 and Mol Cancer Ther (2008); 7(7) p.1880-1889) that PF-00299804 has an acitivity for some types of tumour. PF-00299804 has a structure of:
PF-00299804 [0014] Upon developing the drug having a good antineoplastic effect, being able to reduce the drug resistance and having a good tolerance, the present inventors discover a quinazoline derivative as tyrosine kinase inhibitor having a Pan-HER irreversible inhibition function.
Summary of the Invention [0015] The invention is according to the content of the claims, the present description provides a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof:
[), wherein: R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-3 same or different Q1: C^alkyl, C3_6alkenyl, C3.6alkynyl, C3_8cycloalkyl-C0.6alkyl, 6-10-membered fused ring-C0_galkyl, 7-10-membered spiro ring-C0_6 alkyl and 7-10-membered bridged ring-Co^alkyl, and the carbon atom in said cycloalkyl, said fused ring, said spiro ring and said bridged ring may be optionally replaced by 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O); Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, C^alkyl, C^galkoxyl, C^galkylamino, di(C1_6alkyl)amino, C^galkylcarbonyloxy, C^alkoxylcarbonyl, C^galkylacylamino, C^galkylsulfonyl, C^galkylsulfinyl, C^galkylsulfonylamino and C3_8cycloalkyl; R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-3 same or different Q2: C3^cycloalkyl-C0_6alkyl, 6-10-membered fused ring-C0_galkyl, 7-10-membered spiro ring-C0_6 alkyl and 7-10-membered bridged ring-C0.6alkyl, and the carbon atom in said cycloalkyl, said fused ring, said spiro ring and said bridged ring may be optionally replaced by 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, and when R2 is 7-10-membered bridged ring-C0_6alkyl, R1 is not C3.4cycloalkyl-C0.galkyl or C^alkyl; Q2 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, nitro, trifluoromethyl, C^alkyl, C^galkoxyl, C^galkylamino, di(C1_6alkyl)amino, C^alkylcarbonyloxy, C^alkoxylcarbonyl, C^galkylacylamino, C^galkylsulfonyl, C^galkylsulfinyl and C^alkylsulfonylamino; R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, C1_6alkyl, C2_6alkenyl, C2_galkynyl, C^galkoxyl, C^galkyl substituted with halogen, C^galkoxyl substituted with halogen, C^galkylamino, di(C.|_galkyl)amino, C^galkylthio, C^galkylcarbamoyl, C^galkylcarbonyl, C^alkoxylcarbonyl, C^galkylcarbonyloxy, C-^alkylacylamino, C^galkylsulfonyl, C^galkylsulfinyl and C^alkylsulfonylamino; R3’ is absent; R4, R5and R6 are each independently selected from the group consisting of hydrogen, halogen, C^alkyl, C^galkoxyl, C^galkyl substituted with halogen, C^galkoxyl substituted with halogen, C^alkylamino and di(C.|_galkyl)amino; X is selected from the group consisting of cyano-substituted methenyl or a nitrogen atom; L is selected from the group consisting of O, S(0)m, N(H), N(CH3) or C(O); T is selected from the group consisting of a covalent bond, C(O) or CH(R’), R’ is selected from the group consisting of hydrogen or C^alkyl; Z is hydrogen; q is 2, and R3 may be identical or different; m is selected from the group consisting of 0, 1 or 2; and n is selected from the group consisting of 0 or 1.
[0016] The present invention also describes a pharmaceutical composition containing a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
[0017] The present invention also describes a pharmaceutical formulation containing a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof and a pharmaceutically acceptable carrier.
[0018] The present invention also describes a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof, ora pharmaceutical composition containing a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof as a medicament for treating an excessive proliferative disease and a chronic obstructive pulmonary disease.
[0019] The present invention also describes use of a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or a pharmaceutical composition containing a compound represented by the general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof in the manufacture of a medicamentfortreating an excessive proliferative disease and a chronic obstructive pulmonarydisease.
[0020] The present invention also describes a process for preparing a compound of the general formula (I), comprising the steps of:
Reaction Procedure: [0021]
wherein R1, R2, R3, R3’, R4, R5, R6, X, L, T, Z and q are as defined hereinbefore, Hal1 is selected from the group consisting of Cl, Br and I, Hal2 is selected from the group consisting of Cl and Br, and Hal1 and Hal2 may be identical or different; 1) Dissolving a compound of the starting material (a) in an organic solvent (such as dimethyl formamide (DMF), acetonitrile, tetrahydrofuran (THF), methanol or ethanol), and reacting it with a compound of the formula (V) in the presence of an inorganic base (such as NaH, NaOH or KOH) to produce a compound of the formula (IV); 2) Reacting the compound of the formula (IV) and a reducing agent (such as Fe powder, Zn powder, Pd/C or Raney Ni) to produce a compound of the formula (III); 3) Dissolving the compound of the formula (III) in an organic solvent (such as tetrahydrofuran, dichlormethane (DCM) or ethyl acetate (EA)), and reacting itwith a compound of theformula (b) to produce a compound of theformula (II); and 4) Reacting the compound of the formula (II) and a compound of the formula (c) in the presence of a base (such as A/,A/-diisopropyl ethylamine (DIPEA), triethylamine (TEA), pyridine, K2COs or Na2C03) to produce a compound of the formula (I); where if necessary, a functional group that needs to be protected may be protected, and then deprotected according to the conventional method.
[0022] According to the present invention, the term "C0_6alkyl" means a straight or branched alkyl group having a carbon atom number of 0-6 such as 0, 1,2, 3, 4, 5 or 6. When the carbon atom number is zero, the alkyl is absent. The alkyl includes, for example, "C0_4alkyl", "C^alkyl", "C2_5alkyl", and "C^alkyl". Its example includes but is not limited to, e.g., methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, iso-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethyl-butyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1-me-thyl-2-methylpropyl and the like.
[0023] According to the present invention, the term "C2.6alkenyl" means a straight or branched or cyclic hydrocarbyl group having a double bond and a carbon atom number of 2-6, and includes, for example, "C3_6alkenyl", "C3_5alkenyl", "C2_4alkenyl" and the like. Its example includes but is not limited to, e.g., ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dime-thyl-2-propenyl, 1,2-dimethyl-1 -propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-2-butenyl, 2,2-dimethyl-3- butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl, 1-ethyl-2-methyl-2-propenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, 1,4-hexadienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, 1,4-cyclohexadienyl and the like.
[0024] According to the present invention, the term "C2_6alkynyl" means a straight or branched hydrocarbyl group containing a triple bond and having a carbon atom number of 2-6, including, for example, "C3.6alkynyl", "C3.5alkynyl", "C^alkynyl" and the like. Its example includes but is not limited to, e.g., ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 1-ethyl-2-butynyl, 1 -ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl and the like.
[0025] According to the present invention, the term "C-|_6alkoxyl" means "C^galkyl-O-", wherein C.|_6alkyl is defined as above; including, for example, "C2.5alkoxyl", "C1.4alkoxyl" and the like. Its example includes but is not limited to, e.g., methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, neo-pentoxy, hexyloxy and the like.
[0026] According to the present invention, the term "C^galkylthio" means "C^galkyl-S-", wherein C^galkyl is defined as above, including, for example, "C2_5alkylthio", "C1.4alkylthio" and the like. Its example includes but is not limited to, e.g., methylthio, ethylthio, propylthio, iso-propylthio, butylthio, iso-butylthio, tert-butylthio, sec-butylthio, pentylthio, neo-pentylthio, hexylthio and the like.
[0027] According to the present invention, the term "C-|_6alkylamino" means "C^galkyl-NH-", wherein C^galkyl is defined as above; including, for example, "C2_5alkylamino", "C1_4alkylamino" and the like. Its example includes but is not limited to, e.g., methylamino, ethylamino, propylamino, iso-propylamino, butylamino, iso-butylamino, tert-butylamino, sec-butylamino, pentylamino, neo-pentylamino, hexylamino and the like.
[0028] According to the present invention, the term "di(C.|_galkyl)amino" means "(C1_6alkyl)2-N-", wherein two C^galkyls may be identical or different, and are respectively defined as above.
[0029] According to the present invention, the term "C^galkylcarbonyloxy", "C1_6alkoxylcarbonyl", "C1_6alkylcarbonyl", "C^galkylsulfonyl", "C^galkylsulfinyl", "C^galkylsulfonylamino", "C1_6alkylacylamino" and "C^galkylcarbamoyl" respectively mean "C.|_galkyl-C(0)-0-", "C.|_galkyl-C)-C(0)-", "C.|_6alkyl-C(0)-", "C^galkyl-SC^-", "C^alkyl-SO-", "C^alkyl-S02-NH-", "C1.6alkyi-C(0)-NH-" and "Ci_3alkyl-NH-C(0)-", wherein "C^galkyl" is defined as above.
[0030] According to the present invention, the term "halogen" means fluoro, chloro, bromo, iodo and the like.
[0031] According to the present invention, the term "C3_8cycloalkyl" means a cycloalkyl, which is derived from an alkane containing 3-8, such as 3, 4, 5, 6, 7 or 8 carbon atoms by removing one hydrogen atom, including, for example, "C3.7cycloalkyl", "C3.5cycloalkyl", "C5.6cycloalkyl", "C3_4cycloalkyl" and the like, preferably "C3_6cycloalkyl". Its example includes but is not limited to, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, methyl-cyclopropyl, dimethylcyclopropyl, methylcyclobutyl, dimethylcyclobutyl, methylcyclopentyl, dimethylcyclopentyl, methyl-cyclohexanyl, dimethylcyclohexanyl and the like.
[0032] According to the present invention, the term "6-10-membered fused ring" group means a saturated or unsaturated fused ring group containing 6-10 carbon atoms and formed by the linking of at least two cyclic structures sharing two adjacent atoms with each other, wherein the cyclocarbon atom(s) may be optionally replaced with 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)m, NCH3 and C(O). Its example includes but is not limited to 5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl, 5,6-dihydro-1,7-naphthy-ridin-7(8/-/)-yl, 5H-pyrrolo[3,4-b]pyridin-6(7/-/)-yl, 7,8-dihydropyridino[4,3-d]pyrimidin-6(5H)-yl, 2,3,6,7-tetrahydro-1 /-/-pyrazolo[4,3-c]pyridin-5(4/-/)-y1, 6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl, 3-methyl-6,7-dihydro-3H-pyrazolo[4,5-c]pyridin-5(4/-/)-yl, 2-methylhexahydrocyclopenta[c]pyrrol-5-yl and the like.
[0033] According to the present invention, the term "7-10-membered spiro ring" group means a saturated or unsaturated fused ring group containing 7-10 carbon atoms and formed by at least two rings sharing the same atom, wherein the cyclocarbon atom(s) may be replaced with 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)m, NCH3 and C(O). Its example includes but is not limited to 6-azaspiro[2.5]octan-6-yl, 7-azaspiro[3.5]nonan-7-yl, 8-azaspiro[4.5]decan-8-yl, 1-methyl-1,7-diazaspiro[4.4]nonan-7-yl, 2-methyl-2,6-diazaspiro[3.4]octan-6-yl, 6-azaspiro[3.4]octan-6-yl, 2-oxa-7-azaspiro[4.5]decan-7-yl, 2-oxa-8-aza-spiro[4.5]decan-8-yl, 2-methyl-2,7-diazaspiro[4.5]decane and the like.
[0034] According to the present invention, the term "7-10-membered bridged ring" group means a saturated or unsaturated fused ring group containing 7-10 carbon atoms and formed by any two rings sharing two atoms which are not directly linked, wherein the cyclocarbon atom(s) may be replaced with 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)m, NCH3and C(O). Its example includes but is not limited to (1 S,4S)-2-methyl-2-azabicyclo[2.2.1]hexanyl, 2-azabicyclo[2.2.1]heptanyl, 8-methylbicyclo[3.2.1]oc- tanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-azabicyclo[2.2.2]octanyl, 7-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.2.1]oc-tanyl, 3-azabicyclo[3.3.2]decanyl, 7-oxabicyclo[2.2.1]heptanyl, 8-oxabicyclo[3.2.1]octanyl and the like.
[0035] According to the present invention, the term "a covalent bond" means a single bond for attaching two atoms or groups.
[0036] In a preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q1: C1_4alkyl, Ca.gcycloalkyl-C^alkyl, 6-10-membered fused ring-C0_4alkyl, 7-10-membered spiro ring-C0_4 alkyl and 7-10-membered bridged ring-C0_4alkyl, and the carbon atom in said cycloalkyl, said fused ring, said spiro ring and said bridged ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O); wherein m is selected from the group consisting of 0, 1 or 2, n is selected from the group consisting of 0 or 1, and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, C1.4alkyl, C^alkoxyl, C^alkylamino, diiC^alkylJamino, C1_4alkylcarbonyloxy, C^alkoxylcarbonyl, C1.4alkylacylamino, C^alkylsulfonyl, C1_4alkylsulfinyl, C^alkylsulfonylamino and C3_8cycloalkyl.
[0037] In a further preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q1: (1) C1_4alkyl, cyclopropyl-C0_4alkyl, cyclobutyl-C0_4alkyl, cyclopentyl-C0_4alkyl, cyclohexyl-C0_4 alkyl and cycloheptyl-C0.4alkyl, the carbon atom in said cyclopropyl, said cyclobutyl, said cyclopentyl, said cyclohexyl and said cycloheptyl may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), wherein, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), wherein p is selected from the group consisting of 0, 1 or 2, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl, ethylsulfonyl, meth-ylsulfinyl, methylsulfonylamino, ethylsulfonylamino, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0038] In a further preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by Q1: (1) methyl, ethyl, propyl, cyclopropyl-C0_3alkyl, cyclobutyl-C0_3alkyl, cyclopentyl-C0_3alkyl, cyclohexyl-C0.3alkyl, aze-tidinyl-C0_3alkyl, tetrahydrofuryl-C0.3alkyl, pyrrolidinyl-C0_3alkyl, piperidinyl-C0.3alkyl, morpholinyl-C0_3 alkyl and pip-erazinyl-C0_3alkyl; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), wherein p is selected from the group consisting of 0, 1 or 2, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino.
[0039] In a further preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q1: methyl, ethyl,
and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino.
[0040] In a preferable embodiment according to the compound of the general formula (I), R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q2: cyclopropyl-C0^alkyl, cyclobutyl-C0_4alkyl, 6-10-membered fused ring-C0_4alkyl, 7-10-membered spiro ring-C^alkyl or 7-10-membered bridged ring-C^alkyl, and the carbon atom in said cyclopropyl, said cyclobutyl, said fused ring, said spiro ring and said bridged ring may be replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, wherein m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; Q2 is selected from the group consisting of halogen, hydroxy, amino, cyano, C^alkyl, C^alkoxyl, C1.4alkylamino, diiC^alkylJamino, C^alkylcarbonyloxy, C^alkoxylcarbonyl, C^alkylacylamino, C^alkylsulfonyl, C-,_4alkylsulfinyl and C^alkylsulfonylamino.
[0041] In a further preferable embodiment according to the compound of the general formula (I), R2 is selected from the group consisting of (1) the following groups that are unsubstituted or substituted by 1-2 same or different Q2:
the carbon atom in said ring may be replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring; wherein p is selected from the group consisting of 0, 1 or 2, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, wherein p is selected from the group consisting of 0,1 or 2, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and Q2 is selected from the group consisting of halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl and methylsulfonylamino.
[0042] In a further preferable embodiment according to the compound of the general formula (I), R2 is selected from the group consisting of (1)
that is unsubstituted or substituted by Q2, the carbon atom in said ring may be replaced by 1-2 hetero atoms and/or groups that may be identical ordifferent and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring; wherein p is selected from the group consisting of 0,1 or 2, m is selected from the group consisting of 0,1 or 2, and n is selected from the group consisting of 0 or 1; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, wherein p is selected from the group consisting of 0, 1 or 2, m is selected from the group consisting of 0, 1 or 2, and n is selected from the group consisting of 0 or 1; and Q2 is selected from the group consisting of halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl and methylsulfonylamino.
[0043] In a further preferable embodiment according to the compound of the general formula (I), R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q2:
and Q2 is selected from the group consisting of halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl and methylsulfonylamino.
[0044] In a preferable embodiment according to the compound of the general formula (I), R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, C1.4alkyl, C2_4alkenyl, C2^alkynyl, C1-4a Ikoxyl, C1.4alkyl substituted with halogen, C^alkoxyl substituted with halogen, C^^lkylamino.diiC^alkylJamino.C^^lkylthio, C1_4alkylcarbamoyl, C^alkylcarbonyl, C.|_4alkoxylcarbonyl, C^alkylcarbonyloxy, C^alkylacylamino, C^alkylsulfonyl, C^alkylsulfinyl and C^alkylsulfonylamino.
[0045] In a further preferable embodiment according to the compound of the general formula (I), R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methylamino, ethylamino, dimethylamino, methylthio, methylcarbamoyl, acetyl, methoxycarbonyl, acetoxy, acetylamino and methylsulfonylamino.
[0046] In a further preferable embodiment according to the compound of the general formula (I), R3 is halogen, which is selected from the group consisting of fluoro, chloro, bromo, or iodo.
[0047] In a preferable embodiment according to the compound of the general formula (I), R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, C^alkyl, C.|_4alkoxyl, C^alkyl substituted with halogen, C.|_4alkoxyl substituted with halogen, C^alkylamino and dKC^alkyOamino.
[0048] In a further preferable embodiment according to the compound of the general formula (I), R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, methyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methylamino and dimethylamino.
[0049] In a preferable embodiment according to the compound of the general formula (I), X is a nitrogen atom.
[0050] In a preferable embodiment according to the compound of the general formula (I), L is selected from the group consisting of O, S(0)m or N(H)n; particularly preferably O.
[0051] In a preferable embodiment according to the compound of the general formula (I), T is selected from the group consisting of a covalent bond or CH(R’), R’ is selected from the group consisting of hydrogen or C1 ^alkyl, such as methyl.
[0052] In a further preferable embodiment according to the compound of the general formula (I), T is a covalent bond, accordingly said compound has a structure of the following formula (1-1):
wherein R1, R2, R3, R4, R5, R6, X, L and q are defined as above.
[0053] In a preferable embodiment according to the compound of the general formula (1-1), R3 is halogen, which is selected from the group consisting of chloro orfluoro, X is a nitrogen atom, and said compound has a structure of the following formula (I-2):
wherein R1, R2 and L are defined as above.
[0054] In another preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-3 same or different Q1: C1_4alkyl, C3_8cycloalkyl-C0_4alkyl, 6-10-membered fused ring-C^alkyl, 7-10-membered spiro ring-C0_4 alkyl and 7-10-membered bridged ring-C0-4alkyl, the carbon atom in said cycloalkyl, said fused ring, said spiro ring or said bridged ring may be optionally replaced by 1-3 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, C1_4alkyl, C1_4alkoxyl, C1.4alkylamino, di(C1_4alkyl)amino, C1.4alkylcarbonyloxy, C1.4alkoxylcarbonyl, C1_4alkylacylamino, C1.4alkylsulfonyl, C1_4alkylsulfinyl, C1.4alkylsulfonylamino and C3.8cycloalkyl; R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q2: cyclopropyl-C0_4alkyl, cyclobutyl-C0_4alkyl, 6-10-membered fused ring-C0_4alkyl, 7-10-membered spiro ring-C0.4alkyl or 7-10-membered bridged ring-C0_4alkyl, the carbon atom in said cyclopropyl, said cyclobutyl, said fused ring, said spiro ring or said bridged ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, and when R2 is 7-10-membered bridged ring-C0_4alkyl, R1 is not C3_4cycloalkyl-C0_4alkylorCi_4alkyl; Q2 is selected from the group consisting of halogen, hydroxy, amino, cyano, C14alkyl, C1.4alkoxyl, C1_4alkylamino, di(C1_4alkyl)amino, C1_4alkylcarbonyloxy, C14alkoxylcarbonyl, C1.4alkylacylamino, C1.4alkylsulfonyl, C1.4alkylsulfinyl and C^alkylsulfonylamino; R3 is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, nitro, carbamoyl, C1.4alkyl, C2_4alkenyl, C2.4alkynyl, C14alkoxyl, C1_4alkyl substituted with halogen, C1_4alkoxyl substituted with halogen, C^alkylamino, di(C1.4alkyl)amino, C1_4alkylthio, C^alkylcarbamoyl, C^alkylcarbonyl, C.|_4alkoxylcarbonyl, C1.4alkylcarbonyloxy, C^alkylacylamino, C14alkylsulfonyl, C^alkylsulfinyl and C^alkylsulfonylamino; R3 is absent; R4, R5 and R6 are each independently selected from the group consisting of hydrogen, halogen, C14alkyl, C1_4alkoxyl, C^alkyl substituted with halogen, C^alkoxyl substituted with halogen, C.|_4alkylamino and di(C14alkyl)amino; X is selected from the group consisting of cyano-substituted methenyl or a nitrogen atom; L is selected from the group consisting of O, S(0)m or N(H);
Tis selected from the group consisting of a covalent bond orCH(R’), R’ is selected from the group consisting of hydrogen or methyl; Z is hydrogen; q is 2, and R3 may be identical or different; m is selected from the group consisting of 0, 1 or 2; and n is selected from the group consisting of 0 or 1.
[0055] In another preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by 1-2 same or different Q1: (1) Ci_4alkyl, cyclopropyl-C0_4alkyl, cyclobutyl-C0_4alkyl, cyclopentyl-C0_4alkyl, cyclohexyl-C0_4 alkyl and cycloheptyl-C0.4alkyl, the carbon atom in said cyclopropyl, said cyclobutyl, said cyclopentyl, said cyclohexyl and said cycloheptyl may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O); and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), wherein p is selected from the group consisting of 0, 1 or 2; and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl, ethylsulfonyl, meth-ylsulfinyl, methylsulfonylamino, ethylsulfonylamino, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; R2 is selected from the group consisting of (1)the following groups that are unsubstituted or substituted by 1-2 same or different Q2: or **<> the carbon atom in said ring may be replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure O-C(O)-" is not present in the replaced ring; p is selected from the group consisting of 0, 1 or 2; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, wherein p is selected from the group consisting of 0, 1 or 2, and when R2 is
R1 is not C^alkyl, cyclopropyl-C0.4alkyl or cyclobutyl-C0_4alkyl; and Q2 is selected from the group consisting of halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methyl-amino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl and methylsulfonylami-no; R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methyl-amino, ethylamino, dimethylamino, methylthio, methylcarbamoyl, acetyl, methoxycarbonyl, acetoxy, acetylamino and methylsulfonylamino; R3 is absent; R4, R5and R6 are each independently selected from the group consisting of hydrogen, halogen, methyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methylamino and dimethylamino; X is selected from the group consisting of cyano-substituted methenyl or a nitrogen atom; L is O; T is selected from the group consisting of a covalent bond or CH(R’), R’ is selected from the group consisting of hydrogen or methyl; Z is hydrogen; q is 2, R3 may be identical or different; m is selected from the group consisting of 0, 1 or 2; and n is selected from the group consisting of 0 or 1.
[0056] In a further preferable embodiment according to the compound of the general formula (I), R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by Q1: (1)methyl, ethyl, propyl, cyclopropyl-Co^alkyl, cyclobutyl-C0_3alkyl, cyclopentyl-C0_3alkyl, cyclohexyl-C0_3alkyl, aze-tidinyl-Co^alkyl, tetrahydrofury-ICo^alkyl, pyrrolidinyl-C0_3alkyl, piperidinyl-C0_3alkyl, morpholinyl-C0_3 alkyl and pip-erazinyl-C0.3alkyl; and
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), wherein p is selected from the group consisting of 0, 1 or 2; and Q1 is selected from the group consisting of halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino and diethylamino; R2 is selected from the group consisting of (1)
that is unsubstituted or substituted by Q2, the carbon atom in said ring may be replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring; wherein p is selected from the group consisting of 0, 1 or 2; and (2)
the carbon atom in said ring may be optionally replaced by 1-2 hetero atoms and/or groups that may be identical or different and are selected from the group consisting of O, S(0)m, N(H)n and/or C(O), provided that an ester structure "-O-C(O)-" is not present in the replaced ring, wherein p is selected from the group consisting of 0, 1 or 2; and when R2 is or
R1 is not methyl, ethyl, propyl, cyclopropyl-C0_3alkyl or cyclobutyl-C0.3alkyl; and Q2 is selected from the group consisting of halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methyl-amino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl and methylsulfonylami-no; R3 is selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, carbamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methyl-amino, ethylamino, dimethylamino, methylthio, methylcarbamoyl, acetyl, methoxycarbonyl, acetoxy, acetylamino and methylsulfonylamino; R4, R5and R6 are each independently selected from the group consisting of hydrogen, halogen, methyl, methoxy, methyl substituted with halogen, methoxy substituted with halogen, methylamino and dimethylamino; X is a nitrogen atom; L is O; T is selected from the group consisting of a covalent bond or CH(R’), R’ is hydrogen; Z is hydrogen; q is 2, R3 may be identical or different; m is selected from the group consisting of 0, 1 or 2; and n is selected from the group consisting of 0 or 1.
[0057] In a further preferable embodiment, the compound of the general formula (I) according to the present invention has a structure of the following formula (1-1):
wherein: R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, or diethylamino: methyl, ethyl,
R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl, or methylsulfonylamino:
and when R2 is
R1 is not methyl, ethyl,
R3 is halogen, which is selected from the group consisting of fluoro, chloro, bromo, or iodo; R4, R5 and R6 are each independently hydrogen; X is a nitrogen atom; L is O; and q is 2.
[0058] In a further preferable embodiment, the compound of the general formula (1-1) according to the present invention has a structure of the following formula (I-2):
wherein R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, ordi-ethylamino: methyl, ethyl,
R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetoxy, acetylamino, methylsulfonyl, or methylsulfonylamino:
and when R2 is
R1 is not methyl, ethyl, and
LisO.
[0059] The specific preferable compounds according to the present invention include the following compounds and their pharmaceutically acceptable salts and stereoisomers:
('continued')
(continued)
(continued)
(continued)
[0060] In an embodiment of the preparation method for preparing the compound of the general formula (I) of the present invention, the compound of the general formula (I) of the present invention can be prepared through, for example, the following steps of:
Reaction Procedure: [0061] w
wherein R1, R2, R3, R3, R4, R5, R6, X, L, T, Z and q are defined as above, and Br in formula (b) may be replaced with Cl or I, and Cl can also be replaced with Br;
Step 1: The preparation of a compound of the formula (IV) [0062] A compound of the formula (V) is dissolved an organic solvent (such as DMF, THF, acetonitrile, methanol or ethanol). To the mixure is added an inorganic base (such as NaH, NaOH or KOFI) in batch. The resulting mixture is reacted under stirring at room temperature. Then a compound of formula (a) is added to the reaction mixture. The resulting mixture is reacted under heating to reflux for hours to produce a compound of the formula (IV).
Step 2: The preparation of a compound of the formula (III) [0063] Acompound oftheformula (IV) is added in batch to a mixed solution of a polar organic solvent (such as ethanol, methanol orTFIF) and an acid (such as acetic acid, formic acid, hydrochloric acid or dilute sulfuric acid). To the resulting mixture is then added a reducing agent (such as Fe powder, Zn powder, Pd/C or Raney Ni). The mixture is reacted under heating to produce a compound of the formula (III).
Step 3: The preparation of a compound of the formula (II) [0064] A compound of the formula (III) is dissolved in an organic solvent (such as TFIF, DCM or EA). To the resulting mixture is added a compound of the formula (b) under cooling in an ice-water bath, and then is added dropwise an organic base (such as triethylamine or DIPEA). The mixture is reacted under stirring to produce a compound of the formula (II).
Step 4: The preparation of a compound of the formula (I) [0065] A compound of the formula (II) is dissolved in an organic solvent (such as TFIF, DCM, DMF or acetonitrile). To the resulting mixture is successively added a base (such as DIPEA, TEA, pyridine, K2C03 or Na2C03) and a compound of the formula (c). The mixture is reacted under stirring at room temperature to produce a compound of the formula (I).
[0066] Where if necessary, a functional group that needs to be protected, e.g. hydroxy, amino and the like, may be protected, and then deprotected according to the conventional method.
[0067] The present invention also comprises "a pharmaceutically acceptable salt" of the compound of the formula (I). The pharmaceutically acceptable salt of the compound of the formula (I) of the present invention comprises alkali metal salts, such as Na salt, K salt, Li salt and the like; alkaline-earth metal salts, such as Ca salt, Mg salt and the like; other metal salts, such as A1 salt, Fe salt, Zn salt, Cu salt, Ni salt, Co salt and the like; inorganic base salts, such as ammonium salt; organic base salts, such as tert-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, alkyl phe-nylglycinate salt, ethylene diamine salt, N-methylglucosamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexyl amine salt, Λ/,Λ/’-dibenzylethylene diamine salt, chloroprocaine salt, procaine salt, diethanol amine salt, N-benzyl-phenylethyl amine salt, piperazine salt, tetramethyl amine salt, tris(hydroxymethyl)aminomethane salt and the like; inorganic acid salts, such as halogen acid salt, such as hydrofluoric acid salt, hydrochloride, hydrobromide, hydriodate and the like, nitrate, perchlorate, sulfate, phosphate and the like; organic acid salts, such as lower alkanesulfonate, e.g. mesylate, trifluoromesylate, ethanesulfonate and the like, arylsulfonate, such as benzenesulfonate, para-benzenesul-fonate and the like, carboxylate, such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate, maleate and the like, amino acid salts, such as glycine salt, trimethylglycinate salt, arginine salt, ornithine salt, glutamate salt, asprtate salt and the like.
[0068] The present invention also describes all of possible isomers of the compound of the formula (I). The enantio-morph can be present in case that one or more asymmetric carbon atoms are present in the compound structure; the cis/trans-isomer can be present in case that the compound contains an alkenyl group or a cyclic structure; and the tautomer can be present in case that the compound contains a keto group or a nitrosyl group. All of these isomers and the mixtures thereof are in the scope of the present invention.
[0069] The compound of the general formula (I) of the present description and a pharmaceutically acceptable salt and a stereoisomer thereof can be administered to a mammal, e.g. human orally, parenterally (intravenously, intramuscularly, subcutaneously or rectally and the like), pulmonarily, and locally. The daily dosage of the present compound can be about 1 to about 1000 mg.
[0070] The compound of the general formula (I) of the present description or a pharmaceutically acceptable salt or a stereoisomer thereof can be administered alone or in combination with other therapeutical agents, in particular a second therapeutical agent selected from the group consisting of an antineoplastic agent and an immunosuppressive agent. Said second therapeutical agent is selected from the group consisting of antimetabolite, including but not limited to e.g. capecitabine, gemcitabine and the like; a growth factor inhibitor, including but not limited to e.g. pazopanib, imatinib and the like; an antibody, including but not limited to e.g. herceptin, bevacizumab and the like; a mitotic inhibitor, including but not limited to e.g. paclitaxel, vinorelbine, docetaxel, doxorubicin and the like; antineoplastic hormone, including but not limited to e.g. letrozole, tamoxifen, fulvestrant and the like; alkylating agent, including but not limited to e.g. cyclophosphamide, carmustine and the like; a metal platinum, including but not limited to e.g. carboplatin, cisplatin, oxaliplatin and the like; a topoisomerase inhibitor, including but not limited to e.g. topotecan and the like; an immunosuppressant, including but not limited to e.g. everolimus and the like. All of components to be administered can be administered at the same time or successively and separately in a form of the single formulation or in a combination of the divided formulations.
[0071] The present compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof can be used to treat an excessive proliferative disease and a chronic obstructive pulmonary disease. The excessive proliferative disease includes cancerous disease and non-cancerous disease. The cancerous disease is selected from the group consisting of cerebroma, lung cancer, non-small cell lung cancer, squamous cell, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, mammary cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, adenocarcinoma of esophagus, esophageal squamous cell cancer, solid tumor, non-Hodgkin lymphoma, central nervous system tumor (glioma, gliobastona multiforme, glioma sarcomatosis), prostate carcinoma or thyroid carcinoma; the non-cancerous disease includes for example benign proliferative diseases of skin or prostate.
[0072] The present invention also describes a pharmaceutical composition, containing the compound of the general formula (I) of the present invention, a pharmaceutically acceptable salt, or a stereoisomer thereof as described above and one or more pharmaceutically acceptable carriers. Said composition can be prepared by mixing the compound of the general formula (I) of the present description or a pharmaceutically acceptable salt, or a stereoisomer thereof and one or more conventional pharmaceutically acceptable carrier. Said composition can be prepared into a conventional clinically or pharmaceutically acceptable dosage form to administer orally, parenterally, pulmonarily or locally to the patient in need thereof.
[0073] For the oral administration, The compound of the general formula (I) of the present description or a pharmaceutically acceptable salt, or a stereoisomer thereof can be formulated into a conventional solid preparation, such as tablet, granule, capsule, powder and the like; or the oral liquid preparation, such as an oral solution, an oral suspension, a syrup and the like. For preparing the oral preparation, suitable filler, binder, disintegrant, lubricant, diluent and the like can be added. Conventional filler includes starch, sugar powder, calcium phosphate, calcium sulfate dihydrate, dextrin, microcrystalline cellulose, lactose, pregelatinized starch, mannitol and the like. Conventional binder includes sodium carboxymethylcellulose, PVP-K30, hydroxypropyl cellulose, starch paste, methyl cellulose, ethyl cellulose, hypromellose, gelatinized starch and the like. Conventional disintegrant includes dry starch, polyvinylpolypyrrolidone (cPVP), croscar-mellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose and the like. Conventional lubricant includes magnesium stearate, talc powder, sodium dodecylsulfate, Silica powder and the like. Conventional diluent includes water, ethanol, glycerin and the like.
[0074] Forthe parenteral administration, according to the conventional method, The compound of the general formula (I) of the present description or a pharmaceutically acceptable salt, or a stereoisomer thereof can be formulated into an injectable preparation, including an injection solution, a sterile injection powder and a concentrated injection solution. For preparing the injectable preparation, a conventional method in the pharmaceutical production can be used, and an aqueous solvent or a nonaqueous solvent can be used. The most commonly used aqueous solvent is water for injection. 0. 9% aqueous NaCI solution or other suitable aqeous solution can also be used. The most commonly used nonaqueous solvent is vegetable oil, such as soy oil for injection. The aqueous solution of ethanol, propylene glycol, polyethylene glycol or the like can also be used. For preparing the injectable preparation, an additive can be optionally added, depending on the nature of drug. The additive includes an osmotic regulator, a phi-value regulator, a solubilizer, a filler, an antioxidant, a bacteriostatic agent, an emulsifier, a suspending agent or the like.
[0075] For the rectal, pulmonary or local administration, The compound of the general formula (I) of the present description or a pharmaceutically acceptable salt, or a stereoisomer thereof can be formulated into an inhalant, a sublingual formulation, a gel, an ointment, a suppository, a lotion, a nasal drop, a spraying agent, a transdermal patch and the like according to the conventional method.
[0076] It is demonstrated that the compound of the present invention is a tyrosine kinase inhibitor and has an excellent antineoplastic effect. The compound of the present invention therefore has a good therapeutic effect on an excessive proliferative disease and a chronic obstructive pulmonary disease and reduces the formation of drug resistance. In addition, it is easy to prepare the compound of the present invention; the compound of the present invention has a stable quality, and therefore the compound of the present invention is apt to be produced on the industrial scale.
Best Mode of Carrying Out the Invention [0077] The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. All of the technical solutions that can be accomplished based on the above disclosure fall in the scope of the present invention. 1. The preparation example for the compound of the present invention
Example 1: The preparation of (£)-4-[3-azabicyclo[3.1.0]hexan-3-yl]-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyq uinazolin-6-yl]-2-butenamide (Compound 1) hydrochloride [0078] (1) The preparation of 4-(3-chloro-4-fluorophenylamino)-6-nitro-7-methoxyquinazoline
4-(3-chloro-4-fluorophenyl)amino-6-nitro-7-fluoroquinazoline (25.4 g, 75.4 mmol) and a 50% NaOH solution (7.85 mL, 98.125 mmol) were added to 500 mL methanol. The resulting mixture was reacted at 70°C under reflux for2h. The reaction liquor was poured into ice-water. A large amount of solid separated. After filtering, the filter cake was dried to produce 25.3 g of the target product as yellow solid in a yield of 96.4%. (2) The preparation of 4-(3-chloro-4-fluorophenyl)amino-6-amino-7-methoxyquinazoline
4-(3-chloro-4-fluorophenylamino)-6-nitro-7-methoxyquinazoline (25.3 g, 111 mmol) was dissolved in 500 mL tet-rahydrofuran. To the solution was added 7.6 g Raney-Ni. To the resulting mixture was added hydrogen gas. The mixture was stirred at room temperature for 24h, filtered and rotary-evaporated to remove the solvent. The resulting residue was washed with ethyl acetate to produce 13.345 g 4-(3-chloro-4-fluorophenyl)amino-6-amino-7-methoxy-quinazoline as yellow solid in a yield of 57.7%. 1H-NMR(DMSO-d6, 400 MHz): 610.17 (s, 1H), 9.22 (s, 1H), 8.68 (s, 1H), 8.15 (d, J =4.8 Hz, 1H), 7.78 (br. s„ 1H), 7.35 - 7.55 (m, 2H), 4.05 (s, 3H). (3) The preparation of (£)-4-bromo-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-2-butena mide
bottle, 4-(3-chloro-4-fluorophenyl)amino-6-amino-7-methoxyquinazoline (0.567g, 1.778 mmol) and triethylamine (0.61 mL, 4.387 mmol) were dissolved indissolved in 20 mL tetrahydrofuran. To the reaction bottom was added dropwise at 0°C (£)-4-bromo-2-crotonyl chloride(0.555 g, 3.023 mmol). The resulting mixture was stirred for 1 h with maintaining the temperature. To the reaction liquor was added an appropriate amount of water. The mixture was extracted with dichlormethane. The organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to produce (E)-4-bromo-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazo-lin-6-yl]-2-butena mide (0.742 g in a yield of 89.6%) as yellow solid. (4) The preparation of (£)-4-[3-azabicyclo[3.1.0]hexan-3-yl]-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyq uina-zolin-6-yl]-2-butenamide (Compound 1) hydrochloride
(£)-4-bromo-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-2-butena mide (600mg, 1,29mmol) was dissolved in 20mL THF. To the resulting mixture was added 3-azabicyclo[3.1.0]hexane hydrochloride (200mg, 1.69mmol), and then added dropwise 1mL DIPEA slowly. The mixture was reacted under heating to reflux for 12h. The reaction mixture was concentrated. To the resulting condensate was added an appropriate amount of water. The resulting mixture was extracted with dichlormethane. The organic phase was dried over anhydrous sodium sulfate, and then separated with a silica-gel column (dichlormethane: methanol=5:1) to produce a white solid. The white solid was dissolved in 20mL absolute alcohol. The resulting mixture was reacted with the introduction of hydrogen chloride gas under cooling in an ice-water bath for 0.5h, and then rotary-evaporated to dryness in vaccum to produce 42mg target product of (E)-4-[3-azabicyclo[3.1,0]hexan-3-yl]-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyq uinazolin-6-yl]-2-butenamide hydrochloride in a yield of 6%.
Formula: C24H24CI2FN502 molecular weight: 504.4 mass spectrum (m/e): 468.5(M+1) 1H-NMR (DMSO-d6, 400 MHz): 811.58(br, 1H), 11.43(s, 1H), 10.21(s, 1H), 9.18(s, 1H), 8.89(s, 1H), 7.98(d, 1H), 7.69(br, 1H), 7.58(s, 1H), 7.54(t,1H), 6.97(m, 1H), 6.77(d, 1H), 4.07(s, 3H), 3.98(s, 2H), 3.16(t, 2H), 1.75(br, 2H), 1.20(m, 2H), 1.16(m, 1H), 0.61(m, 1H).
Example 2: The preparation of (£)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-[azaspiro[3.3]hep tan-2-yl]-2-butenamide (Compound 2) hydrochloride [0079]
(1) The preparation of cyclobutane-1,1-diyldimethanol
Cyclobutane-1,1-dicarboxylic acid (28.8g, 0.2mol) was dissolved in lOOmLTHF. To the resulting mixture was added in batch lithium aluminum hydride (22g, 0.58mol) under cooling in an ice-water bath. The mixture was reacted at room temperature for 10h. The reaction was quenched with ethyl acetate and water. The resulting reaction mixture was dried over anhydrous sodium sulfate, filtered, and rotary-evaporated to remove the solvent to produce 21.3g target product as yellow oil in a yield of 92%. The crude product was directly used in the next step without purification. (2) The preparation of cyclobutane-1,l-diylbis(methylene) dimethanesulfonate
The crude product obtained in the previous step was dissolved in lOOOmL dichlormethane and 15mL triethylamine. To the resulting mixture was added dropwise MsCI (61.56g, 0.55mol) undercooling in an ice-water bath. The reaction was continued for 3h. After filtering, the filtrate was concentrated to dryness to produce 52.6g target product as yellow solid. The crude product was directly used in the next step without purification. (3) The preparation of 2-tosyl-2-azaspiro[3.3]heptane
The crude cyclobutane-1,l-diylbis(methylene) dimethanesulfonate (25.3g, 0.09mmol) and potassium carbonate (27.6g, 0.2mol) were dissolved in 200mL DMSO. To the resulting mixture was added p-toluenesulfonamide (34.2g, 0.2mol) at room temperature. The mixture was reacted for 12h under heating to 110°C. The reaction system was cooled. To the mixture was added 1000mL ethyl acetate. The mixture was washed with water. The organic layer was dried over anhydrous sodium sulfate, and rotary-evaporated to dryness. The resulting residue was separated with a silica-gel column (petroleum ether: ethyl acetate=7:1) to produce 14.74g target product as colorless oil in a yield of 65%. (4) The preparation of 2-azaspiro[3.3]heptane
2-tosyl-2-azaspiro[3.3]heptanes (7.3g, 0.03mol) was dissolved in 30mL 1,2-dimethoxyethane. To the resulting mixture was added dropwise 50mL of a fresh-made sodium naphthalene solution under cooling in ice-water. The resulting mixture was reacted at room temperature for 1h. The reaction was quenched with water. The reaction liquor was concentrated and then purified with a silica-gel column (dichlormethane:methanol=20: 0-1: 0) to produce 2.41g 2-azaspiro[3.3]heptane in a yield of 83%. (5) The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-[2-azaspiro[3.3]h eptan-2-yl]-2-butenamide hydrochloride
(£)-4-bromo-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-2-butena mide (595mg, 1.28mmol), 2-azaspiro[3.3]heptane(415mg, 4.25mmol) and potassium carbonate (781 mg, 5.66mmol) were dissolved in 50mL acetonitrile. The resulting mixture was reacted at 60°C for 10h. The mixture was cooled to room temperature. To the mixture was added 100mL water. The mixture was extracted with dichlormethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was separated with a silica-gel column (dichlormethane: methanol=20:1) to produce 72.5mg yellow solid in a yield of 12%. The yellow solid (150mg, 0.31 mmol) was dissolved in 10mLhydrogen chloride/ethanol. The resulting mixture was reacted at room temperature for 2h. The reaction liquor was rotary-evaporated to dryness to produce the target product (E)-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-[azaspiro[3.3]hep tan-2-yl]-2-butenamide hydrochloride.
Formula: C25H26Cl2FN502 molecular weight: 518.4 mass spectrum (m/e): 482.2 (M+1) 1H-NMR(CDCI3, 400 MHz): 89.09(s, 1H), 8.63(s, 1H), 8.10(s, 1H), 7.88(d, 1H), 7.71(br, 1H), 7.50(br, 1H), 7.23(s, 1H), 7.10(br, 1H), 6.90(m, 1H), 6.13(d, 1H), 4.04(s,3H), 3.24(br, 6H), 2.13(t, 4H), 1.82(t, 2H).
Example 3: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-azaspiro[3.4]o ctan-2-yl) -2-butenamide (Compound 14) [0080]
[0081] In a dried reaction vessel, (£)-4-bromo-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-2-bute-na mide (0.742 g, 1.59 mmol), 2-azaspiro[3,4]octane hydrochloride (0.307 g, 2.082 mmol) and anhydrous potassium carbonate (0.663 g, 4.797 mmol) were dissolved in 25 mL DMF. The resulting mixture was stirred at room temperature for24h. To the resulting reaction liquor was added an appropriate amount of water. The resulting mixture was extracted ethyl acetate. The organic phases were combined. The combined mixture was successively washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified with a silica-gel column chromatography (dichlormethane: methanol=20:1), and then treated with acetonitrile, to produce 110 mg of A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-azaspiro[3.4]octan -2-yl)-2-butenamide as pale yellow solid in a yield of 13.9%.
Formula: C26H27CIFN502 molecular weight: 496.0 mass spectrum (m/e): 496.2(M+1) 1H-NMR (DMSO-d6, 400 MHz): 69.79 (s, 1H), 9.69 (s, 1H), 8.90 (s, 1H), 8.51 (s, 1H), 8.06 - 8.18 (m, 1H), 7.71 - 7.84 (m, 1H), 7.41 (t, J = 9.0 Hz, 1H), 7.27 (s, 1H), 6.71 (dt, J = 15.3, 4.8 Hz, 1H), 6.51 (d, J = 15.3 Hz, 1H), 4.00 (s, 3H), 3.19 (d, J = 3.3 Hz, 2H), 3.06 (s, 4H), 1.69 (br. s., 4H), 1.49 (br. s., 4H).
Example 4: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-azaspiro[3.5]n onan-2-yl)-2-butenamide (Compound 15) [0082]
[0083] (E)-4-bromo-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-2-butena mide (3.06g, 6.6mmol) and 2-azaspiro[3.5]nonane hydrochloride (2.13g, 13.2mmol) were dissolved in 10mL DMF. To the resulting mixture was added K2C03 (2.73g, 19.8mmol). The mixture was stirred at room temperature for 30min. After the completion of reaction, 50mL waterwas added. The resulting mixture was extracted with ethyl acetate. The organic phase was rotary-evaporated to dryness. The resulting solid was purified with a silica-gel column (dichlormethane: methanol=15:1) to produce 1.21g (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-azaspiro[3.5]n onan-2-yl)-2-butenamide in a yield of 36%.
Formula: C27H2gCIFN502 molecular weight: 510.0 mass spectrum (m/e): 510.2 (M+1) 1H-NMR(MeOD-d6, 400 MHz): 69.26(s 1H),8.76(s, 1H), 7.93(d, 1H), 7.67-7.63(m, 1H),7.40(t, 1H),7.38 (s, 1H), 7.00-6.89 (m, 1H),6.81 (d, 1H),4.19(s, 3H), 4.02(d, 2H), 3.49-3.45 (d, 2H), 3.04-3.00 (t, 2H), 2.08-1,60(m, 10H).
Example 5: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(7-azaspiro[3.5]n onan-7-yl)-2-butenamide (Compound 17) [0084]
[0085] According to the method of Example 3, 2-azaspiro[3,4]octane hydrochloride was replaced with 7-aza-spiro[3.5]nonane hydrochloride to produce 1.21g (£)-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(7-azaspiro[3.5]n onan-7-yl)-2-butenamide in a yield of 36%.
Formula: C27H29CIFN502 molecular weight: 510.0 mass spectrum (m/e): 510.2 (M+1) 1H-NMR(MeOD-d6, 400 MHz): 69.26(s,1H), 8.76(s, 1H), 7.93(d, 1H), 7.67-7.63(m, 1H), 7.38(t, 1H), 7.32(s, 1H), 6.93-6.89 (m, 1H), 6.77(d, 1,0H), 4.37(d, 2H), 4.19-4.05(m, 5H), 3.49-3.48(d, 2H), 2.04-1,78(m, 5H), 1.56-1.29(m, 5H).
Example 6: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(4-azaspiro[2.4]h eptan-4-yl)-2-butenamide (Compound 25) [0086]
[0087] According to the method of Example 3, 2-azaspiro[3,4]octane hydrochloride was replaced with 4-aza-spiro[2.4]heptane hydrochloride to produce 0.825g (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(4-azaspiro[2.4]h eptan-4-yl)-2-butenamide in a yield of 26%.
Formula: C25H25CIFN502 molecular weight: 482.0 mass spectrum (m/e): 482.2 (M+1) 1H-NMR(MeOD-d6, 400 MHz): 69.26(s,1H), 8.76(s, 1H), 7.93 (d, 1H), 7.67-7.63 (m, 1H), 7.40 (t, 1H), 7.34 (s, 1H), 6.89-6.88 (m, 1H), 6.77 (d, 1.0H), 4.19 (s, 3H), 4.05-3.92 (m, 2H), 3.49-3.46 (d, 2H), 2.42-1.99 (m, 4H), 1.56-1.29 (m, 4H).
Example 7: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(5-azaspiro[2.4]h eptan-5-yl) -2-butenamide (Compound 26) [0088]
[0089] According to the method of Example 3, 2-azaspiro[3.4]octane hydrochloride was replaced with 5-aza-spiro[2.4]heptane hydrochloride to produce the target compound.
Formula: C25H25CIFN502 molecular weight: 482.0 mass spectrum (m/e): 482.2(M+1) 1H-NMR (DMSO-d6, 400 MHz) δ: 9.80 (s, 1H), 9.69 (s, 1H), 8.86- 8.99 (m, 1H), 8.52 (s, 1H), 8.06- 8.18 (m, 1H), 7.75-7.87 (m, 1H), 7.41 (t, J = 9.0 Hz, 1H), 7.27 (s, 1H), 6.76 - 6.91 (m, 1H), 6.59 (d, J = 15.6 Hz, 1H), 4.00 (s, 3H), 3.24 (m, 2H), 2.60 - 2.77 (m, 2H), 1.74 (m, 2H), 0.51 (m, 4H).
Example 8: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(6-azaspiro[3.4]n onan-6-yl) -2-butenamide (Compound 27) [0090]
[0091] According to the method of Example 3, 2-azaspiro[3,4]octane hydrochloride was replaced with 6-aza-spiro[3.4]octane hydrochloride to produce the target compound.
Formula: C26H27CIFN502 molecular weight: 496.0 mass spectrum (m/e): 496.2(M+1) 1H-NMR (DMSO-d6, 400 MHz) δ: 9.80 (s, 1H), 9.71 (br.s., 1H), 8.91 (s, 1H),8.52(s, 1H), 8.09-8.15 (m, 1H), 7.75-7.82 (m, 1H), 7.41 (t, J = 9.0 Hz, 1H), 7.27 (s, 1H), 6.80 (dt, J = 15.2, 5.8 Hz, 1H), 6.58 (d, J = 15.3 Hz, 1H), 4.00 (s, 3H), 3.27 (br. s„ 2H), 2.59 (s, 4H), 1.71 -2.02 (m, 8H).
Example 9: The preparation of (£)-/\/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-oxa-6-azaspiro [3.5] nonane)-6-yl)-2-butenamide (Compound 28) [0092]
[0093] According to the method of Example 3, 2-azaspiro[3.4]octane hydrochloride was replaced with 2-oxa-6-aza-spiro[3.5]nonane hydrochloride to produce 0.71g of the target compound (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-oxa-6-azaspiro [3.5]nonane)-6-yl)-2-butenamide in a yield of 21%.
Formula: C26H27CIFN503 molecular weight: 512.0 mass spectrum (m/e): 512.2 (M+1) 1H-NMR(CDCI3-d6, 400 MHz): 69.11(s,1 H), 8.63(s, 1H), 7.96(d, 1H), 7.68-7.60 (m,2H), 7.34(s, 1H), 7.04(t, 1H), 6.22(d, 1H), 4.42(d, 4H), 4.08(d, 3H), 3.25 (d, 2H), 2.40 (s, 2H), 2.22-2.20 (m, 2H),2.02 (m, 2H), 1.59-1.56(m, 2H).
Example 10: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(2-oxa-7-azaspiro [3.5] nonan-7-yl) -2-butenamide (Compound 29) [0094]
[0095] According to the method of Example 4, 2-azaspiro[3.4]octane hydrochloride was replaced with 2-oxa-7-aza-spiro[3.5]nonane hydrochloride to produce the target compound. Formula: C26H27CIFN503 molecular weight: 512.0 mass spectrum (m/e): 512.2(M+1) 1H-NMR (DMSO-d6, 400 MHz) 6: 9.79 (s, 1H), 9.69 (s, 1H), 8.91 (s, 1H), 8.52 (s, 1H), 8.12 (dd, J = 6.8, 2.3 Hz, 1H), 7.79 (dt, J = 8.5, 3.5 Hz, 1H), 7.41 (t, J = 9.2 Hz, 1H), 7.27 (s, 1H), 6.77 (dt, J = 15.3, 6.0 Hz, 1H), 6.55 (d, J = 15.3 Hz, 1H), 4.26 (s, 4H), 4.00 (s, 3H), 3.07 (d, J = 5.8 Hz, 2H), 2.27 (br. s„ 4H), 1.78 (br. s„ 4H).
Example 11: The preparation of (E)-A/-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-(6-azaspiro[2.5]o ctan-6-yl)-2-butenamide (Compound 30) [0096]
[0097] According to the method of Example 4,2-azaspiro[3.4]octane hydrochloride was replaced with 6-aza-spiro[2.5]octane hydrochloride to produce the target compound.
Formula: C26H27CIFN502 molecular weight: 496.0 mass spectrum (m/e): 496.2(M+1) 1H-NMR (DMSO-d6, 400 MHz) 6: 9.79 (s, 1H), 9.69 (s, 1H), 8.91 (s, 1H), 8.52 (s, 1H), 8.12 (dd, J = 6.8, 2.3 Hz, 1H), 7.79 (dt, J = 8.3, 3.5 Hz, 1H), 7.41 (t, J = 9.2, 1H), 7.27(s, 1H), 6.82 (dt, J = 15.2, 6.1 Hz, 1H), 6.57 (d, J = 15.6 Hz, 1H), 4.00 (s, 3H), 3.16 (d, J = 4.8 Hz, 2H), 2.42 (br. s„ 4H), 1.35 (br. s„ 4H), 0.24 (s, 4H).
[0098] The following compounds could also be prepared according to the above-mentioned methods:
(continued)
(continued)
II. In vitro assays for the antineoplastic activities of the present compounds [0099] Hereinafter, the beneficial effects of the present compounds will be illustrated by in vitro enzyme inhibitory activity and in vitro cellular inhibitory activity. However, it should be noted that the beneficial effects of the present compounds are not limited to the effects as illustrated below.
Assay 1
In vitro enzyme inhibitory activity of the present compounds Samples: [0100] Controls: PF-00299804, lab-made; Gefitinib, purchased from Anqing worldchem Co., LTD.; Erlotinib hydrochloride, purchased from Anqing worldchem Co., LTD.; Lapatinibditosylate, purchased from Taizhou Xingcheng Chemp-harm Co., Ltd.; referring to the section "Background Art" hereinabove for the structures of the above-mentioned four compounds; and
The present compounds: lab-made, their chemical names and structural formulae are shown in the preparation examples. Assay procedures: [0101] The abbreviations used in the following assay have the following meanings: HEPES: hydroxyethyl piperazine ethanesulfonic acid;
Brij-35: polyethylene glycol lauryl ether; DTT: dithiothreitol;
Coating Reagent #3: #3 coating agent; EDTA: ethylene diamine tetraacetic acid, purchased from Sigma Co. Ltd.; FAM labeled peptide: fluorescein labeled peptide 22 (GL Biochem); ATP: adenosine triphosphate (Sigma); DMSO: dimethyl sulfoxide; EGFR: human epidermal growth factor receptor (Carna); HER2: human epidermal growth factor receptor 2 (Carna); HER4: human epidermal growth factor receptor 4 (Carna). 1. Formulating the agents to be used in the assay (1) 1.25-fold MnCI2-free kinase buffer (62.5 mM HEPES, PH 7.5, 0.001875% Brij-35, 12.5 mM MgCI2, 2.5 mM DTT); (2) 1.25-fold MnCI2-containing kinase buffer (62.5 mM HEPES, pH 7.5, 0.001875% Brij-35,12.5 mM MgCI2, 12.5 mM MnCI2, 2.5 mM DTT); (3) Stop buffer (100 mM HEPES, pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent #3, 50 mM EDTA); (4) 2.5-fold kinase solutions (to the 1.25-fold kinase buffers were added the corresponding kinases to formulate 2.5-fold EGFR, HER2, HER4 kinase solutions); (5) 2.5-fold peptide solutions (to the 1.25-fold kinase buffers were added FAM labeled peptide and ATP to formulate the peptide solutions); (6) 5-fold compound solutions (using 100% DMSO to formulate 50-fold compound solutions having different concentration gradients, and diluting with water by 10 times to obtain 5-fold compound solutions having different concentration gradients); 2. Adding 5μί of a 5-fold compound solution to a 384-well plate; 3. Adding 10 μί of a 2.5-fold kinase solution to incubate for 10min; 4. Then adding 10μί of a 2.5-fold peptide solution, and reacting at 28°C for 1 h; and 5. Finally, adding 25μί of stop buffer to terminate the reaction, and reading the data with Caliper. 6. Curve fitting to obtain an IC50 value.
The calculated inhibition ratio (%)=(the maximum conversion rate - the conversion rate)/(the maximum conversion rate - the minimum conversion rate)x 100 [0102] The curve fitting was conducted with the Xlfit software to obtain IC50 values.
The results: [0103] See Table 1 below.
Table 1 In vitro enzyme inhibitory activity
Conclusion: [0104] It can be seen from Table 1 that the present compounds have stronger inhibitory activities on EGFR, HER2 and HER4 kinases. The present compounds have a remarkably better inhibitory activity on the EGFR kinase than Lapatinib ditosylate; the present compounds have a remarkably better inhibitory activity on the HER2 kinase than Gefitinib and Erlotinib hydrochloride; the present compounds have a remarkably better inhibitory activity on the HER4 kinase than Erlotinib hydrochloride and Lapatinib ditosylate; and the present compounds are comparable with PF-00299804 in the inhibitory activities on EGFR, HER2 and HER4 kinases.
Assay 2
In vitro cellular inhibitory activity of the present compounds Samples: [0105] Controls: PF-00299804, lab-made; Gefitinib, purchased from Anqing worldchem Co., LTD.; Erlotinib hydrochloride, purchased from Anqing worldchem Co., LTD.; Lapatinib ditosylate, purchased from TaizhouXingcheng Chemp-harm Co., Ltd.; and
The present compounds: lab-made, their chemical names and structural formulae are shown in the preparation examples.
Materials and Apparatuses in Assay:
(continued)
Assay procedures: [0106] 1. Formulating the agents and the compounds 1) Formulating PBS: NaCI (8g), KCI (0.2g), Na2HP04(1.44g), and KH2P04 (0.24g) were added to ultrapure water (800mL). After adjusting the phi to 7.4, ultrapure water was further added until the volume reached 1L. The mixture was autoclaved for 20 min. 2) Formulating the XTT working liquor: XTT powder (100mg) was taken and, while being kept in darkness, dissolved into 300ml of the serum-free RPMI1640 culture medium that was warmed to 50°C and did not contain phenol red. The mixture was filtered, packaged separately, and used immediately or within one week. It is necessary for all of the processes to be kept in darkness. 3) Formulating test compounds • Formulating a stock solution of test compound:
The compound powder was dissolved into DMSO until a concentration of 10 mM reached. • Formulating gradient dilute solutions of test compound:
First, the 10mM stock solution of test compound was diluted with DMSO in a 4-fold successive gradient for 10 concentrations. 2 μι. DMSO-diluted compound was added to 998μΙ_ of the culture medium containing 10% FBS. Therefore, the maximum concentration of the compound is 20μΜ, the concentration of DMSO is 0.2%, and there are 10 concentration gradients in total. 2. Culturing cells 1) Thawing cells: • A cell-freezing tube was removed from liquid nitrogen, and placed in a water bath of 37°C-39°C to thaw the cells quickly. • A freezing-preserving solution was transfered to 15 ml sterile centrifuge tube, to which was added a culture medium in a volume 10 times largerthanthatofthefreezing-preserving solution. The mixture was centrifuged at 1000 rpm at 4°C for 5 min. The culture medium in the centrifuge tube was discarded, and then a culture medium containing 10% FBS was added. The cells were resuspended and transferred to the culture bottle. On the next day, the solution was changed. 2) Passing cells • For the logarithmic growth phase cells, the culture medium was discarded and an appropriate volume of PBS was added to wash the cells once. Then an appropriate volume of a digestive juice containing 0.25% pancreatic enzyme and 0.02% EDTA was added. The solution was placed on stand at 37°C for 2-5 min, and then washed once with PBS after the digestive juice was discarded. An appropriate volume of a culture medium containing 10% FBS was added to terminate the digestion. The pipette was blown and hit slightly, and the cells were digested down to produce a cell suspension for cell passage and further experiment. 3) Freezing and preserving cells • For the logarithmic growth phase cells, a digestive juice containg 0.25% pancreatic enzyme and 0.02% EDTA was used to digest cells to produce a cell suspension. The suspension was centrifuged at 1000 rpm at 4 °C for 5 min. The culture medium was discarded and a freezing-preserving solution containing 10% DMSO and 90% FBS was added to resuspend the cells. The cells were packaged separately in the cellfreezing tubes in 2X106 cells/tube. The cell-freezing tubes were placed in a programmed cooling cassette, kept at -80°C for 24 hours, and then transferred to liquid nitrogen for freezing and preserving. 3. Plating Cells 1) Praparing the cell suspension • The culture medium was removed from the culture bottle. The cells were rinsed twice with PBS. The pancreatic enzyme was added to digest cells. The digested cells were collected by centrifuge. The cells were resuspended with a culture medium containing 10% fetal calf serum, counted and adjusted to an appropriate concentration (the cell viability should be over 90%). The cell concentration was 5xl04/ml. 2) The cell suspension was added to the 96-well plate, 100 μι. per well. 3) The plate was placed in the incubator and incubated at 37°C under 5% C02 overnight. 4. Treating with drugs
Drugs were added to the cell culture plate. The plate was placed in the incubator and incubated at 37°C under 5% C02 for 72 hours. 5. Testing the cell viability with the XTT method
The XTT working solution was added to the plate. The plate was placed in the incubator and incubated at 37°C under 5% C02 for 2 hr. Then the plate was placed in a microplate reader to read the absorbance at 450 nm. 6. Data processing 1) The percent inhibition was calculated by the following calculation. %inhibition=(Absorbance(medium) - Absorbance(Compound))/(Absorbance(medium) -Absorbance(positive control)x 100%; 2) Data were input into GraphPad Prism 5.0 to plot a curve and obtain IC50.
Result: [0107] See the Tables 2-4 below.
Table 2 in vitro cellular inhibitory activities on H1975 (NSCLC, non-small cell lung cancer)
(continued)
Table 3 in vitro cellular inhibitory activities on SKOV3 (Ovarian carcinoma)
Table 4 in vitro cellular inhibitory activities on A431 (Epidermoid carcinoma)
Conclusions: [0108] It can be seen from Table 2 that the cellular proliferation inhibition effect of the present compounds on H1975 (NSCLC, non-small cell lung cancer) is remarkably superior to Erlotinib hydrochloride, Lapatinib ditosylate and PF-00299804.
[0109] It can be seen from Table 3 that the cellular proliferation inhibition effect of the present compounds on SKOV3 (Ovarian carcinoma) is remarkably superiorto Erlotinib hydrochloride, and is comparable with PF-00299804 and Lapatinib ditosylate.
[0110] It can be seen from Table 4 that the cellular proliferation inhibition effect of the present compounds on A431 (Epidermoid carcinoma) is remarkably superior to Erlotinib hydrochloride, Lapatinib ditosylate and PF-00299804. Claims 1. A compound represented by the general formula (I-2), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
wherein R1 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, carboxyl, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, or diethylamino: methyl, ethyl,
and
R2 is selected from the group consisting of the following groups that are unsubstituted or substituted by halogen, hydroxy, amino, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, ace-toxy, acetylamino, methylsulfonyl, or methylsulfonylamino:
and L is O. 2. The compound according to claim 1 ora stereoisomer thereof, ora pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:
3. A compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:
and
4. A pharmaceutical composition, which contains the compound according to anyone of claims 1-3, ora stereoisomer thereof, or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition according to claim 4, which further contains a second therapeutical agent selected from the group consisting of an antineoplastic agent and an immunosuppressive agent, said second therapeutical agent is selected from the group consisting of an antimetabolite, including capecitabine and gemcitabine; a growth factor inhibitor, including pazopanib and imatinib; an antibody, including herceptin and bevacizumab; a mitotic inhibitor, including paclitaxel, vinorelbine, docetaxel, and doxorubicin; an antineoplastic hormone, including letrozole, tamoxifen, and fulvestrant; an alkylating agent, including cyclophosphamide and carmustine; a metal platinum, including carboplatin, cisplatin, and oxaliplatin; a topoisomerase inhibitor, including topotecan; and an immunosuppressant, including everolimus. 6. A pharmaceutical formulation containing a compound according to any one of claims 1-3, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers. 7. The compound according to anyone of claims 1-3, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for use in treating an excessive proliferative disease or a chronic obstructive pulmonary disease. 8. The compound for use according to claim 7, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein said excessive proliferative disease includes a cancerous disease and a non-cancerous disease, the cancerous disease is selected from the group consisting of cerebroma, lung cancer, non-small cell lung cancer, squamous cell, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, mammary cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, adenocarcinoma of esophagus, esophageal squamous cell cancer, solid tumor, non-Hodgkin lymphoma, central nervous system tumor (glioma, gliobastona multiforme, glioma sarcomatosis), prostate carcinoma or thyroid carcinoma; and the non-cancerous disease is benign proliferative diseases of skin or prostate. 9. A process for preparing a compound according to claim 1, comprising the steps of:
Reaction Procedure:
wherein R1, R2, R3, R3’, R4, R5, R6, X, L, T, Z and q are as defined in claim 1, Hal1 is selected from the group consisting of Cl, Br and I, Hal2 is selected from the group consisting of Cl and Br, and Hal1 and Hal2 may be identical or different; 1) Dissolving a compound of the starting material (a) in an organic solvent, and reacting it with a compound of the formula (V) in the presence of an inorganic base to produce a compound of the formula (IV); 2) Reacting the com pound of the formula (IV) and a reducing agent to produce a com pound of the formula (II I); 3) Dissolving the compound of the formula (III) in an organic solvent, and reacting it with a compound of the formula (b) to produce a compound of the formula (II); and 4) Reacting the compound of the formula (II) and a compound of the formula (c) in the presence of a base to produce a compound of the formula (I); where if necessary, a functional group that needs to be protected may be protected, and then deprotected according to a conventional method.
Patentanspriiche 1. Verbindung dargestellt durch die allgemeine Formel (I-2) Oder ein Stereoisomer davon Oder ein pharmazeutisch annehmbares Salz davon: wobei
R1 ausgewählt ist aus der Gruppe bestehend aus den folgenden Gruppen, die nicht substituiert oder durch Halogen, Hydroxy, Amino, Carboxyl, Cyano, Methyl, Ethyl, Methoxy, Ethoxy, Methylamino, Ethylamino, Dime-thylamino oder Diethylamino substituiert sind: Methyl, Ethyl,
und
R2 ausgewählt ist aus der Gruppe bestehend aus den folgenden Gruppen, die nicht substituiert oder durch Halogen, Hydroxy, Amino, Methyl, Ethyl, Methoxy, Ethoxy, Methylamino, Ethylamino, Dimethylamino, Diethyl-amino, Acetoxy, Acetylamino, Methylsulfonyl oder Methylsulfonylamino substituiert sind:
und L O ist. 2. Verbindung gemäß Anspruch 1 oder ein Stereoisomer davon oder ein pharmazeutisch annehmbares Salz davon, wobei die Verbindung ausgewählt ist aus der Gruppe bestehend aus:
3. Verbindung Oder ein Stereoisomer davon oderein pharmazeutisch annehmbares Salzdavon, wobei die Verbindung ausgewahlt ist aus der Gruppe bestehend aus:
und
4. Pharmazeutische Zusammensetzung, die die Verbindung gemäß einem der Ansprüche 1-3 oder ein Stereoisomer davon oder ein pharmazeutisch annehmbares Salz davon enthält. 5. Pharmazeutische Zusammensetzung gemäß Anspruch 4, die ferner einen zweiten therapeutischen Wirkstoff ausgewählt aus der Gruppe bestehend aus einem antineoplastischen Wirkstoff und einem immunsuppressiven Wirkstoff enthält, wobei der zweite therapeutische Wirkstoff ausgewählt ist aus der Gruppe bestehend aus einem Antimetabolit, einschließlich Capecitabin und Gemcitabin; einem Wachstumsfaktor-Inhibitor, einschließlich Pazopanib und Imati-nib; einem Antikörper, einschließlich Herceptin und Bevacizumab; einem mitotischen Inhibitor, einschließlich Paclitaxel, Vinorelbin, Docetaxel und Doxorubicin; einem antineoplastischen Hormon, einschließlich Letrozol, Tamoxifen und Fulvestrant; einem Alkylierungsmittel, einschließlich Cyclophosphamid und Carmustin; einem metallischen Platin, einschließlich Carboplatin, Cisplatin und Oxaliplatin; einem Topoisomerase-Inhibitor, einschließlich Topotecan; und einem Immunsuppressivum, einschließlich Everolimus. 6. Pharmazeutische Formulierung umfassend eine Verbindung gemäß einem der Ansprüche 1-3 oder ein Stereoisomer davon oder ein pharmazeutisch annehmbares Salz davon und einen oder mehrere pharmazeutisch annehmbare Träger. 7. Verbindung gemäß einem der Ansprüche 1-3 oderein Stereoisomer davon oderein pharmazeutisch annehmbares Salz davon zur Verwendung zur Behandlung einer exzessiven proliferativen Erkrankung oder einer chronisch obstruktiven Lungenerkrankung. 8. Verbindung zur Verwendung gemäß Anspruch 7 oder ein Stereoisomer davon oder ein pharmazeutisch annehmbares Salz davon, wobei die exzessive proliferative Erkrankung eine krebsartige Erkrankung und eine nicht krebsartige Erkrankung einschließt, wobei die krebsartige Erkrankung ausgewählt ist aus der Gruppe bestehend aus Cerebroma, Lungenkrebs, nichtkleinzelligem Lungenkrebs, Plattenepithelkrebs, Blasenkarzinom, Magenkrebs, Eierstockkrebs, Bauchfellkrebs, Bauchspeicheldrüsenkrebs, Brustkrebs, Kopf- und Halskrebs, Gebärmutterhalskrebs, Endometriumkrebs, Dickdarmkrebs, Leberkrebs, Nierenkarzinom, Adenokarzinom des Ösophagus, Ösophagus plattenepithelkrebs, fester Tumor, Non-Hodgkin Lymphom, Tumor im zentralen Nervensystem (Gliom, Glioblastoma multiforme, Gliom Sarkomatose), Prostatakarzinom oder Schilddrüsenkarzinom und die nicht krebsartige Erkrankung gutartige proliferative Erkrankungen der Haut oder der Prostata ist. 9. Verfahren zur Herstellung einer Verbindung gemäß Anspruch 1, umfassend die Schritte:
Reaktionsvorgang:
wobei R1, R2, R3, R3, R4, R5, R6, X, L, T, Z und q wie in Anspruch 1 definiert sind, Hai1 ausgewählt ist aus der Gruppe bestehend aus CI, Br und I, Hai2 ausgewählt ist aus der Gruppe bestehend aus CI und Br und Hai1 und Hai2 identisch oder unterschiedlich sein können; 1) Auflösen einer Verbindung des Ausgangsmaterials (a) in einem organischen Lösungsmittel und Reagieren mit einer Verbindung der Formel (V) in Anwesenheit einer anorganischen Base, um eine Verbindung der Formel (IV) herzustellen; 2) Reagieren der Verbindung der Formel (IV) und eines Reduktionsmittels, um eine Verbindung der Formel (III) herzustellen; 3) Auflösen der Verbindung der Formel (III) in einem organischen Lösungsmittel und Reagieren mit einer Verbindung der Formel (b), um eine Verbindung der Formel (II) herzustellen; und 4) Reagieren der Verbindung der Formel (II) und einer Verbindung der Formel (c) in Anwesenheit einer Base, um eine Verbindung der Formel (I) herzustellen; wo falls nötig eine funktionelle Gruppe, die geschützt werden muss, geschützt und dann gemäß einer konventionellen Methode entschützt werden kann.
Revendications 1. Composé représenté par la formule générale (1-2), ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci :
dans lequel R1 est choisi dans le groupe constitué des groupes suivants qui sont non substitués ou substitués avec un halogène, un hydroxy, un amino, un carboxyle, un cyano, un méthyle, un éthyle, un méthoxy, un éthoxy, un méthylamino, un éthylamino, un diméthylamino, ou un diéthylamino : un méthyle, un éthyle, I 9
et
R2 est choisi dans le groupe constitué des groupes suivants qui sont non substitués ou substitués avec un halogène, un hydroxy, un amino, un méthyle, un éthyle, un méthoxy, un éthoxy, un méthylamino, un éthylamino, un diméthylamino, un diéthylamino, un acétoxy, un acétylamino, un méthylsulfonyle, ou un méthylsulfonylamino :
et L est O. 2. Composé selon la revendication 1 ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel ledit composé est choisi dans le groupe constitué de :
r
3. Compose, ou un stereoisomere de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel ledit compose est choisi dans le groupe constitue de :
4. Composition pharmaceutique, qui contient le composé selon l’une quelconque des revendications 1 à 3, ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. 5. Composition pharmaceutique selon la revendication 4, qui contient en outre un second agent thérapeutique choisi dans le groupe constitué d’un agent antinéoplasique et d’un agent immunosuppresseur, ledit second agent thérapeutique est choisi dans le groupe constitué d’un antimétabolite, notamment la capécitabine et la gemcitabine ; un inhibiteur de facteur de croissance, notamment le pazopanib et l’imatinib ; un anticorps, notamment l’herceptine et le bévacizumab ; un inhibiteur mitotique, notamment le paclitaxel, la vinorelbine, le docétaxel, et la doxorubicine ; une hormone antinéoplasique, notamment le létrozole, le tamoxifène, et le fulvestrant ; un agent alkylant, notamment le cyclophosphamide et la carmustine ; un platine métallique, notamment le carboplatine, le cisplatine, et l’oxaliplatine ; un inhibiteur de topoisomérase, notamment le topotécan ; et un immunosuppresseur, notamment l’évérolimus. 6. Formulation pharmaceutique contenant un composé selon l’une quelconque des revendications 1 à 3, ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci et un ou plusieurs supports pharmaceutiquement acceptables. 7. Composé selon l’une quelconque des revendications 1 à 3, ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci pour son utilisation dans le traitement d’une maladie proliférative excessive ou d’une bronchopneumopathie chronique obstructive. 8. Composé pour son utilisation selon la revendication 7, ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, dans lequel ladite maladie proliférative excessive comprend une maladie cancéreuse et une maladie non cancéreuse, la maladie cancéreuse est choisie dans le groupe constitué d’un cérébrome, d’un cancer du poumon, d’un cancer du poumon non à petites cellules, d’un carcinome malpighien, d’un carcinome de la vessie, d’un cancer gastrique, d’un cancer des ovaires, d’un cancer péritonéal, d’un cancer pancréatique, d’un cancer mammaire, d’un cancer de la tête et du cou, d’un cancer du col de l’utérus, d’un cancer de l’endomètre, d’un cancer colorectal, d’un cancer du foie, d’un carcinome rénal, d’un adénocarcinome de l’oesophage, d’un cancer malpighien de l’oesophage, d’une tumeur solide, d’un lymphome non hodgkinien, d’une tumeurdu système nerveux central (gliome, glioblastome multiforme, gliome sarcomatose), d’un carcinome de la prostate ou d’un carcinome de la thyroïde ; et la maladie non cancéreuse est une maladie proliférative bénigne de la peau ou de la prostate. 9. Procédé de préparation d’un composé selon la revendication 1, comprenant les étapes suivantes :
Procédure réactionnelle :
dans lequel R1, R2, R3, R3’, R4, R5, R6, X, L, T, Z et q sont tels définis dans la revendication 1, Hal1 est choisi dans le groupe constitué de Cl, Br et I, Hal2 est choisi dans le groupe constitué de Cl et Br, et Hal1 et Hal2 peuvent être identiques ou différents ; 1) la dissolution d’un composé du produit départ (a) dans un solvant organique, et sa réaction avec un composé de la formule (V) en présence d’une base inorganique pour produire un composé de la formule (IV) ; 2) la réaction du composé de la formule (IV) et d’un agent réducteur pour produire un composé de la formule (ni); 3) la dissolution du composé de la formule (III) dans un solvant organique, et sa réaction avec un composé de la formule (b) pour produire un composé de la formule (II) ; et 4) la réaction du composé de la formule (II) et d’un composé de la formule (c) en présence d’une base pour produire un composé de la formule (I) ; si nécessaire, un groupe fonctionnel qui doit être protégé peut être protégé, et ensuite déprotégé selon un procédé classique.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • WO 9738983 A [0009] · US 20040044014 A1 [0011] • US 20010044435A1 [0010]
Non-patent literature cited in the description • Bioorganic &amp; Medicinal Chemistry, 2008, vol. 16, · Cancer Res, 2007, vol. 67 (24), 11924-11932 [0013] 3482-3488 [0007] · Mol Cancer Ther, 2008, vol. 7 (7), 1880-1889 [0013] • Adv Ther, 2011, vol. 28 (2), 1-8 [0012]

Claims (5)

  1. I, (1-2) -általános képleiű vegyöietek, vsgy azok szisreolzommjd, vagy egek győgyszerésxsiileg eltagadható sók ahol
    RJ :|akíMé.skt a §?$bsxtk«áiaüan vagy balogéra, hldrexi", amino-a karboxiK dana··., metál·-, etil«, metoxi-, etoxK metái-aramo·-·, etil-amino«, dimetlbamlao'·,, vagy dieiil-amino-csoporttal szahszíHoák következő csoportokból: .maiik etil.,. és s
    álló csoportból választjuk; R*· jolebtését a KSUbszutuálaílan fagy halógétK hidroxb. amiúo-;; ffietik, etil·, metoxK etok-K metlbammo·', etikaüimo-’, dirnetlbasuinoy díétikábtiftó-» acetóxiy Meíd-ami» ηθ'\ rnetü-sxuHbniK vagy ?netil»8z»lfo«ií-ami«o-csQpoíttal szobSztiiuált követted csoportokból:
    álló csoportból választjuk; és L jelentése (X
  2. 2> Az L igénypöut szerinti vegyül etek vagy esek sstereoizomerjei, vagy -esek gyógyssetósseíiieg elfogadható sói ahol a vegyüietet az alábbiakból, álló csoportból választjuk:
  3. 3* Vegyülitek, vagy ezek s*.tereo)xomeqei, vagy ezek gyógyszere szeüleg elíbgadMtó sói, ahol a-vegyöletft az alábbiakból álló csoportból választjuk;
  4. 4, mnely :&amp;ζ b-3, igénypontok bármelyike szemoií wgyik letet, vagy ennek szíeteolzomoh^b vagy ennek gyógyszerésxeüleg elfogadható sóit tartalmazza.
  5. 5, Á 4. igénypont szétfőtt gyógyseiieittmóny, amely továbbá tartalmaz egy második hatóanyagot, amelyet az· anüneoplaszhkus szerekből és az inttmmszupresziv szerek» hói Utó xtátezia*%.« É0Vf^j# 'mtoáife'MióMpgöt az aMimelabolitokhéh hete- értve á kapecltaMnt é$ pmettabinb a. növekedést bsktor inhibitorokból, beleértve a pazop#*· nibót la az tmatmihetj atnitestekbóh baleésive a bereepífbt és bevaeiznmabot; a mftoókux hibltotokbók belélttve a p.^h?ayeh; vlnomíHm, doeetaxek, és doxoruhietni; az antioeoptas·^ tlius hormonokból, beleértve a letrtí§öih tamoxifent, és iMvestrantoil m alkiiexö szerekből, beleértvé a dfclöfószíamtdot és a karmnsxtinu a piaiina témhől, beleértve a kithoplatbu, cisz-plattot, Ix oxaliplaftoh s lopoizomeráz inhibitorokból, beleértve a topóiéként; és m toumm-sxopresszánsokbóh beleértve az everolimuszL álló csoportból választunk, &amp; Oyégp^#|s®iá»y*.'i®J»ely a* Kh igénypontok bármelyike szerinti vegyü-leteket, vagy ezek sztoreoizepteridk vagy ezek gyégyszerészelileg elfogadható sóit és egy vagy több gyógpzemszeileg elfogadható hordozói tartat máz. '% Az 1-3. igénypontok bármelyike szerinti vegyületek, vagy ezek szíemnixemer-jel vagy ezek győgyszevészetileg elfogadható sói exeesszly pr&amp;llforácios betegség krónikus obstrukdv légúti betegség kezelésében történő alkalmazásra. I, Vegyületek, vagy ezek sztereoizomerjei, vagy ezek gyógyszerészetileg elfogadható sói a 7. igénypont szerinti alkalmazásra, ahol az. excessziv proliterációs betegség rákos megbetegedésre és nem-rákos megbetegedésre vonatkozik, a rákos megbetegedést az alábbiakból álló csoportból választjuk: cersbvóma, tüdőrák, nem-kisejtes tüdőrák, laphám sejt, hólyag kareinóma, gyomorrák, petefészekrák, periioneális rák, hasnyálmirigy rák, emlőrák,; fej és nyak! rák, méhnyak rák, méhtestrák, végbálrák, máj rák, vese karcinóma, nyelőcső adenokarcinóma, nyelőcső laphámsejt rák, szolid tumor, nem-Hodgkin iiinlőpta, központi idegrendszeri tumor (giioma, giiobasztoma nmliiform, glioma szarkomatozisj, prosztátá kér-cinóma vagy paizsttohgy k-smiímmaf és a nétb-tdkos megbetegedés á bőr vagy proszfotaplh-dulatú bmjánzásos megbetegedései, % Iljárás í, igénypont szerinti vegyületek előállltásáM, amely a kővetkező llpé-seket fartrdmazzz·.; Á reakció folyamata:
    ahol R!> lé, 11^· 1·?» RÁ Z és qjel$giésraz' t. igéi|?p^»tba® mégkMföMíR, Hal5 jelentését «®,."Br ésTMtéí alkotott csoportból választjuk, Hal2 jelentését aQ % Br áltat alkotott csoportból választjuk, és Har és Hal*5· lebél,azonos vagy &amp;ö- lönböző; Π A kiindulási anyag (a) vegyületének feloldása egy szerves oldószerben, és reagáítatása (V) képlett vegyülette) egy szerveden bázis jelenlétében (IV) képiem vegyidet előállítására; 2j Ateaiáiatása a (III) képlete vegyület előállttá-»sám; 3 t A (III) képiéit! egy szerves cdRőszerhetg M reagitatása (b) képletü ve-, gyillettel (II) képtetü vegyület előállítására; és 4) A (II) képletű vegyület és íc) képletü vegyület (|: képlete vegvoiet elő diiuisárn, ahol ha szükséges, eay védendő mnkciés csoport védhető, és ezután egy szokásos eljárással a védőcsoport eltávolítható.
HUE12788871A 2011-05-26 2012-05-28 Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása HUE033575T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110138115 2011-05-26

Publications (1)

Publication Number Publication Date
HUE033575T2 true HUE033575T2 (hu) 2017-12-28

Family

ID=47216604

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12788871A HUE033575T2 (hu) 2011-05-26 2012-05-28 Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása

Country Status (7)

Country Link
US (2) US9586939B2 (hu)
EP (1) EP2716633B1 (hu)
JP (1) JP5859118B2 (hu)
CN (1) CN103748080B (hu)
DK (1) DK2716633T3 (hu)
HU (1) HUE033575T2 (hu)
WO (1) WO2012159457A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
HUE033575T2 (hu) 2011-05-26 2017-12-28 Xuanzhu Pharma Co Ltd Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
WO2014177038A1 (en) 2013-04-28 2014-11-06 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN107892684B (zh) * 2013-07-18 2020-05-26 锦州奥鸿药业有限责任公司 喹唑啉衍生物及其药物组合物，以及作为药物的用途
CN108602797B (zh) * 2015-12-25 2020-08-25 山东轩竹医药科技有限公司 喹唑啉衍生物的晶体及其制备方法
EP3395811B1 (en) * 2015-12-25 2020-05-13 Xuanzhu Pharma Co., Ltd. Crystals of quinazoline derivative and preparation method therefor
US11111234B2 (en) 2016-08-12 2021-09-07 Xuanzhu Pharma Co., Ltd. Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
CN107721987A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721986A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN108078990B (zh) * 2016-11-23 2023-06-02 山东轩竹医药科技有限公司 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途
CN109071498B (zh) * 2017-02-16 2021-03-30 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
CN110963972A (zh) * 2019-11-21 2020-04-07 苏州明锐医药科技有限公司 一种喹唑啉衍生物及其制备方法与药物用途
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
TWI820414B (zh) * 2020-04-17 2023-11-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、製備方法及其應用
CN112920103A (zh) * 2021-03-02 2021-06-08 康化（上海）新药研发有限公司 一种温和制备2-氮杂螺[3.3]庚烷盐酸盐的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
EP2896612A1 (en) 1998-09-29 2015-07-22 Wyeth Holdings LLC Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
ES2280375T3 (es) 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO.KG Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion.
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
ES2374553T3 (es) * 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-fenilamino-quinazolin-6-il-amidas.
US7253288B2 (en) 2004-09-08 2007-08-07 Pacific Scientific Energetic Materials Company Process for preparing substituted tetrazoles from aminotetrazole
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CZ2006592A3 (cs) 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
HUE033575T2 (hu) 2011-05-26 2017-12-28 Xuanzhu Pharma Co Ltd Tirozin-kináz inhibitor kinazolin származék, elõállítási eljárása és alkalmazása

Also Published As

Publication number Publication date
JP5859118B2 (ja) 2016-02-10
JP2014515358A (ja) 2014-06-30
WO2012159457A1 (zh) 2012-11-29
CN103748080B (zh) 2016-09-28
EP2716633A4 (en) 2014-10-29
EP2716633A1 (en) 2014-04-09
US20170136023A1 (en) 2017-05-18
US20140161801A1 (en) 2014-06-12
US9586939B2 (en) 2017-03-07
CN103748080A (zh) 2014-04-23
US9956222B2 (en) 2018-05-01
DK2716633T3 (en) 2017-07-17
EP2716633B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
DK2716633T3 (en) QUINAZOLINE DERIVATIVE AS A TYROSIN-KINASE INHIBITOR, PROCEDURE FOR PREPARING IT AND USING THEREOF
DK2612860T3 (en) QUINAZOLINE DERIVATIVES SUBSTITUTED WITH ANILIN, METHOD OF PREPARING AND USING THEREOF
TWI586659B (zh) ４－喹唑啉胺衍生物在醫藥上的應用
CN104736155B (zh) 双环化合物作为激酶的抑制剂
ES2339174T3 (es) N-(aril- o heteroaril)-pirazo(1,5-a)pirimidinas 3-sustituidas como inhibidores de cinasa.
BRPI0619272A2 (pt) 3-(amino substituìdo)-pirazolo[3,4-d]pirimidinas como inibidores de quinase ephb e vegfr2
HUE034568T2 (hu) Kinazolin-inhibitorok epidermális növekedési faktor-receptorok mutáns formáinak aktiválásának gátlására
BRPI0619517A2 (pt) ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase
JP2013536253A5 (hu)
BRPI0718269A2 (pt) Derivados de pirazol fundido substituído por 3-aminocarbonila como moduladores de proteína cinase
JP2009533472A (ja) 癌治療法
EP3661935A1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
CN106892922B (zh) 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
JP7036798B2 (ja) キナゾリン誘導体の塩の結晶
CN103965119A (zh) 含有锌结合基的不可逆egfr酪氨酸激酶抑制剂
CN102452989B (zh) 苯胺取代的喹唑啉衍生物
CN113087671B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
BRPI0717873A2 (pt) Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases
CN106146525B (zh) 三并环类间变性淋巴瘤激酶抑制剂
CN104557955B (zh) 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
WO2022121967A1 (zh) Egfr酪氨酸激酶抑制剂及其用途
TW201213333A (en) Crystal forms of tricyclic pyrazolopyrimidine derivative
CN105579459A (zh) 四并环类间变性淋巴瘤激酶抑制剂
TW201202240A (en) Quinazoline compounds